Industry insiders refute ill-intended hype on early inoculation of Sinopharm Group s leaders, owe speed to mature technology, urgent situation
Wang Qi and Leng Shumei Published: Mar 09, 2021 09:12 PM
Workers unload a container of China s Sinopharm inactivated coronavirus vaccines at the Belgrade Airport, Serbia, January 16, 2021. Photo: Xinhua
The recent disclosure by China s pharmaceutical giant Sinopharm Group boss Yu Qingming that some of the firm s leaders received the COVID-19 vaccine as early as March 2020, about three months after the outbreak started in Wuhan, Central China s Hubei Province, amazed many, while also prompting some ill-intended Western media hype of a conspiracy theory.
However, industry insiders and vaccine experts reached by the Global Times on Tuesday pointed out that such speedy vaccine progress is a result of China s mastering of mature inactivated vaccine technology and researchers determination amid an urgent need at the early stage of the outbrea
China to support WHO on setting up vaccination mutual recognition platform
Liu Caiyu Published: Mar 09, 2021 09:22 PM
People display their cards after getting the coronavirus vaccine on the outskirts of Kathmandu, Nepal. Nepal will administer the second dose of the COVID-19 vaccine from April 20 to April 28 to those who have received the first shot of the vaccine from January 27 to February 12. The first dose of the COVID-19 vaccine was given to health professionals, security personnel, officials of diplomatic missions, embassies, and those working in the United Nations. Photo: AFP
The World Health Organization (WHO) on Monday once again expressed practical and ethical concerns over using a vaccination passport as a certificate for international travel, while China on the same day launched its version of a health code for people who travel abroad.
Serious adverse reactions of Sinovac COVID-19 vaccine in HK are within the expected range: experts
Chen Qingqing Published: Mar 09, 2021 12:01 AM
Co-convenor of Hong Kong s Expert Committee on Clinical Events Assessment Following COVID-19 Immunization Ivan Hung (C) at a press conference in Hong Kong, south China on March 3, 2021.(Photo: Xinhua)
A Hong Kong expert team said Monday that they deemed that the second death case in the city following vaccination of Sinovac vaccines was not related to the vaccine as the autopsy report showed that the cause of death of the recipient, a 55-year-old woman, was myocardial infarction and she had an aortic laceration.
China Defends Its Low-Effectiveness Vaccine After Hong Kong Man Dies
3 Mar 2021
Chinese health authorities and state media aggressively defended “Coronavac,” a Chinese coronavirus vaccine candidate by the Chinese firm Sinovac, on Wednesday after a 63-year-old Hong Kong man died this week following the administration of his first dose.
Coronavac is the first of two Chinese-made coronavirus vaccines approved by the Communist Party. Scoring at a little over 50-percent effectiveness rate in preventing Chinese coronavirus infections, it is considered among the lowest-quality vaccines currently approved for distribution on a large-scale level. It is particularly ineffective compared to two of the three vaccines approved for emergency use in the United States: the vaccine by Pfizer, which is 95 percent effective, and the Moderna product, testing at 94-percent effectiveness.
Link between HK man s death and Sinovac vaccine highly unlikely globaltimes.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globaltimes.cn Daily Mail and Mail on Sunday newspapers.